ProMIS Neurosciences Inc.

PMN:TSX; PMN:NCM

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded proteins implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts.

streetwise book logo Streetwise Company Fact Sheet

2024/5/22 5:25:37

(PMN:TSX - PMN:NCM)

Streetwise Reports Articles

08/10/2022 - View Article
07/01/2022 - View Article